Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda

Launched by AFRICA POWER LIMITED · Jan 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new device called Mossie-GO, which releases a substance to help protect against malaria, a disease spread by mosquitoes. The trial aims to see how effective this device is in reducing malaria cases in children under 5 years old in Uganda. Children in participating households will be tested for malaria using simple tests, and researchers will also look at how the device affects mosquito behavior and resistance to insecticides.

To participate in this study, families need to have a child aged 5 or younger and agree to use the device according to provided instructions. Each selected household will receive either the active device with special discs that help repel mosquitoes or a control device with no active ingredient. Families will be monitored over about 18 months, and they can continue using other malaria prevention methods like bed nets. Participation also involves answering surveys and allowing researchers to collect data to help understand the device's impact. This trial is an opportunity for families to contribute to important research that could help reduce malaria in their community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Cluster level:
• • Number of households \> 100
• Household level:
• • Presence of a child ≤ 5 years of age at point of enrolment in the study
• • Adult head of household agrees to receiving and using the device as per manual instructions
• • Adult head of household agrees to data collection visits and household surveys
• • Children within household sleeps in cluster \> 90% of nights during any given month
• Individual level:
• • ≤ 5 years of age when enrolled into the study
• • No plans for extended travel (\> 1 month) outside of home during study
• • Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
• • Provision of informed consent form (ICF) by the parent(s) or guardian
• • Participants not on regular malaria prophylaxis
• Exclusion Criteria:
• Cluster level:
• • Number of households \< 100
• Household level:
• • Presence of a child \> 5 years of age at point of enrolment in the study
• • Adult head of household does not agree to data collection visits and household surveys
• • Children within household sleeps in cluster \< 90% of nights during any given month
• • Households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile).
• Individual level:
• • \>5 years of age when enrolled into the study
• • Plans for extended travel (\> 1 month) outside of home during study
• • Participating or planned participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
• • No provision of ICF signed by the parent(s) or guardian
• • Participants on regular malaria prophylaxis